Derek Woolner, MD, FRCPC

Northwest Dermatology & Laser Centre

600 Crowfoot Crescent NW, Suite 225
Calgary, Alberta, Canada
T3G 0B4
403-247-7070

 

Specialty: Dermatology

Dr. Derek Woolner, Dermatologist, Specialist in Psoriasis 

Research Interests: Acne, Actinic Keratoses, Atopic Dermatitis, Basal Cell Carcinoma, Cosmetics, Psoriasis, Psoriatic Arthritis, Rosacea, Seborrheic Dermatitis

 

In 1996, Dr. Derek Woolner began his dermatology practice in his hometown of Calgary, Alberta. In 2000 Dr. Woolner began participating in clinical research trials and since then has conducted clinical trials for dermatologic conditions such as psoriasis, seborrhoeic dermatitis, and acne.

Dr. Woolner is an active part of the local medical community. He is on the medical staff of 3 major hospitals in Calgary: Peter Lougheed Hospital, Rockyview General Hospital, and Alberta Children's Hospital. Dr. Woolner's current positions also include Clinical Assistant Professor at the University of Calgary.

Dr. Woolner is a member of numerous associations including the Canadian Dermatology Association, Alberta Society of Dermatology, Canadian Medical Association, American Academy of Dermatology and the American Board of Dermatology.

 

Click to view Dr. Derek Woolner's Publications

Papp KA, Menter MA, Abe M, Elewski B, Feldman SR, Gottlieb AB, Langley R, Luger T, Thaci D, Buonanno M, Gupta P, Proulx J, Lan S, Wolk R, OPT Pivotal 1 and OPT Pivotal 2 investigators. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials. Br J Dermatol 2015 Oct; 173(4): 949-61. PMID: 26149717 / doi: 10.1111/bjd.14018

Griffiths CE, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, Cameron GS, Erickson J, Zhang L, Secrest RJ, Ball S, Braun DK, Osuntokun OO, Heffernan MP, Nickoloff BJ, Papp K, UNCOVER-2 and UNCOVER-3 investigators. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet 2015 Aug 8; 386(9993): 541-51. Epub 2015 Jun 10. PMID: 26072109 / doi: 10.1016/S0140-6736(15)60125-8

Tan J, Humphrey S, Vender R, Barankin B, Gooderham M, Kerrouche N, Audibert F, Lynde C, POWER study group. A treatment for severe nodular acne: a randomized investigator-blinded, controlled, noninferiority trial comparing fixed-dose adapalene/benzoyl peroxide plus doxycycline vs. oral isotretinoin. Br J Dermatol 2014 Dec; 171(6): 1508-16. Epub 2014 Oct 28. PMID: 24934963 / doi: 10.1111/bjd.13191

Eichenfield LF, Jarratt M, Schlessinger J, Kempers S, Manna V, Hwa J, Liu Y, Graeber M, Adapalene Lotion Study Group. Adapalene 0.1% lotion in the treatment of acne vulgaris: results from two placebo-controlled, multicenter, randomized double-blind, clinical studies. J Drugs Dermatol 2010 Jun; 9(6): 639-46. PMID: 20645525

Woolner DB, Soltani K. “Pigment Abnormalities”. In: R. Rakel (Ed.), Conn’s Current Therapy. W.B. Saunders Company: Philadelphia, Pennsylvania, USA, 1997.

Woolner D, Soltani K. Management of hand dermatitis. Compr Ther 1994; 20(7): 422-426. PMID: 7924232

Copyright 2014 Probity Medical Research Inc. All Rights Reserved.

Login